Many countries cannot afford to buy existing COVID-19 vaccines, a collective approach is needed.
Academic rigor, journalistic flair
Articles on Pfizer
Displaying 1 - 20 of 34 articles
Researchers say around 70% of the US needs to get the coronavirus vaccine to stop the pandemic. But questions around the vaccines and regional differences add some uncertainty to that estimate.
So far, the only COVID-19 vaccines authorized for use need to be kept frozen. But there are many places in the world that can't support a cold supply chain.
A new strain of the SARS-CoV-2 virus that causes COVID-19 appears to be spreading fast in the UK. This probably isn't a big problem, but the data isn't in yet.
COVID-19 vaccines have very specific storage requirements that make shipping a difficult task. Two ideas – fulfillment centers and cross-docking – could help overcome some distribution challenges.
We should applaud drug companies for developing COVID-19 vaccines in record time, but let’s not be under any illusion about the profits that are motivating them.
Millions of Americans say they won't get the vaccine. Will money change their minds? And is luring them with cash the right approach?
COVID-19 vaccine testing on children is just getting started, and only in adolescents.
The vaccines that will first be used to prevent the spread of COVID-19 will have gone through a special approval process with the FDA. but just what is this expedited process?
The side effects of new SARS-CoV-2 vaccines are a result of immune system activation. While uncomfortable, they are both normal and expected. They are a sign that the vaccine is working.
'Sensible' public figures have far less influence on our behaviour than it seems
Because Pfizer-BioNTech and Moderna vaccines have been developed in record time, many wonder whether companies cut corners or compromised safety.
Pfizer and BioNTech have announced 95% efficacy for their mRNA vaccine, having met the final target they need to before seeking regulatory approval.
Two pharma companies have announced early COVID-19 vaccine trial results with over 90 per cent effectiveness. What does that mean for getting back to normal?
There are two new COVID-19 vaccines that appear to be more than 90% effective. But what are these vaccines, and how are they different from those used previously?
Moderna's shot is far easier to store and distribute than Pfizer's. But there are concerns neither vaccine performs particularly well for older people.
The recent vaccine trial results certainly look impressive, but here's how to fully interrogate what they mean.
Interim analysis of trial data isn't unusual – but leaves us with many things we still need to find out.
With COVID-19 cases soaring across the US and worldwide, the need for a vaccine could not be greater. Here's where we stand on vaccine development, including positive results from Pfizer's trial.
Early analysis suggests this vaccine has an efficacy of over 90%. So if you took ten people who were going to get sick from COVID-19 and vaccinated them, only one would get sick.
Top contributors
-
Professor of Business, University of Michigan
-
Professor of Medicine, University of Virginia
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Ken Harvey is a Friend of The Conversation.
Associate Professor, School of Public Health and Preventive Medicine, Monash University
-
Emeritus Professor of Accounting, University of Essex, University of Essex
-
Professor of Pharmaceutical Biology, Monash University
-
Lecturer in Law, Ulster University
-
Professor of Immunology and Pro Vice-Chancellor, Research Partnerships, Victoria University
-
Professor of Law and Public Health, The Ohio State University
-
Assistant researcher, University of Sydney
-
Distinguished Professor of Management & Global Business, Rutgers University
-
Science Writer, Queensland Brain Institute, The University of Queensland
-
Professor of Law, Boston University
-
Assistant Professor of Law, Saint Louis University
-
Associate Professor and Course Leader: Post Graduate Programmes in Clinical Pharmacy in the Department of Pharmacy, Sefako Makgatho Health Sciences University
